Aimee Chantelle Broussard, APRN
Psychiatric/Mental Health · Broussard, LANPI 1710209044
Payments from drug & device makers
Across 785 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Johnson & Johnson$884
- Lundbeck LLC$782
- plus $6K from 26 others
What the payments were for
- Food & beverage$13,157100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 182 | $2,237 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 74 | $1,220 |
| Otsuka America Pharmaceutical, Inc. | 70 | $1,170 |
| Alkermes, Inc. | 70 | $1,163 |
| Johnson & Johnson | 38 | $884 |
| Lundbeck LLC | 37 | $782 |
| Corium, LLC | 43 | $679 |
| Axsome Therapeutics, Inc. | 24 | $593 |
| Sunovion Pharmaceuticals Inc. | 52 | $491 |
| Neurocrine Biosciences, Inc. | 25 | $479 |
| Noven Therapeutics, LLC | 26 | $470 |
| Vanda Pharmaceuticals Inc. | 19 | $403 |
| Tris Pharma Inc | 20 | $368 |
| Braeburn Inc. | 16 | $347 |
| Indivior Inc. | 13 | $279 |
| Bausch Health US, LLC | 14 | $259 |
| Teva Pharmaceuticals USA, Inc. | 12 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $207 |
| Abbott | 1 | $164 |
| Supernus Pharmaceuticals, Inc. | 9 | $161 |
| Eisai Inc. | 7 | $123 |
| Boston Scientific | 1 | $75 |
| Merck | 4 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Ironshore Pharmaceuticals Inc. | 3 | $55 |
| Neos Therapeutics, LP | 3 | $55 |
| Sage Therapeutics, LLC | 2 | $54 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Stryker | 1 | $28 |
| Noven Pharmaceuticals, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Diamondback Peripheral$164
- INVEGA SUSTENNA$150
- Auvelity$104
How this compares
$13,157 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 30 | $225,368 |
| VraylarCariprazine Hcl | 121 | $177,948 |
| Invega SustennaPaliperidone Palmitate | 25 | $75,183 |
| CaplytaLumateperone Tosylate | 11 | $17,442 |
| TrintellixVortioxetine Hydrobromide | 34 | $16,261 |
| Lurasidone Hcl | 109 | $13,132 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $12,880 |
| DayvigoLemborexant | 23 | $7,440 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $6,506 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 223 | $6,369 |
| Duloxetine Hcl | 488 | $5,660 |
| Aripiprazole | 177 | $5,476 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $3,908 |
| Lisdexamfetamine Dimesylate | 12 | $2,314 |
| Trazodone Hcl | 270 | $2,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $479 | $225,36830 claims |
| AbbVieVraylar | $2,237 | $177,948121 claims |
| Johnson & JohnsonInvega Sustenna | $884 | $75,18325 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $207 | $22,76751 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,220 | $17,44211 claims |
| Axsome Therapeutics, Inc.Auvelity | $593 | $12,88012 claims |
| Eisai Inc.Dayvigo | $123 | $7,44023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Broussard
- Amber LittlefieldBroussard$225K
- Natalie BlanchardBroussard$12K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.